{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:47Z","timestamp":1792806167748,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidad de Navarra","id":[{"id":"https:\/\/ror.org\/02rxc7m23","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Human papillomavirus (HPV) is a necessary causal factor for most cervical cancers and contributes to several other HPV-related malignancies. The nonavalent HPV vaccine targets the most prevalent oncogenic genotypes and has the potential to prevent up to 90% of HPV-attributable cancers. However, cervical cancer screening remains essential, as vaccination does not cover all oncogenic HPV genotypes, does not treat established HPV infection, and cannot prevent disease in individuals after HPV exposure. Available Spanish data do not yet show a clear sustained decline in HPV-related cancers comparable to that reported in some other high-income countries. This narrative review examines HPV vaccination, cervical cancer screening, and the burden of HPV-related cancers in Spain, with a focus on implementation gaps, surveillance limitations, and opportunities for improvement. Strengthening vaccination coverage, population-based screening, follow-up after abnormal results, and national data integration will be essential to accelerate progress toward cervical cancer elimination.<\/jats:p>","DOI":"10.1007\/s12094-026-04447-w","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T17:44:32Z","timestamp":1780767872000},"page":"5143-5153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HPV-related cancer prevention in Spain: progress and remaining challenges in vaccination, screening, and surveillance"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-0449","authenticated-orcid":false,"given":"Alejandro Gallego","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonzalez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Chiva","family":"de Agustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"4447_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2023.200258","volume":"15","author":"CW Nelson","year":"2023","unstructured":"Nelson CW, Mirabello L. Human papillomavirus genomics: understanding carcinogenicity. Tumour Virus Res. 2023;15:200258. https:\/\/doi.org\/10.1016\/j.tvr.2023.200258.","journal-title":"Tumour Virus Res"},{"key":"4447_CR2","unstructured":"Pan American Health Organization. Human papillomavirus: frequently asked questions (IM-HPV-FAQ). Available at: https:\/\/www.paho.org\/sites\/default\/files\/2020-05\/IM-HPV-FAQ_e.pdf (Accessed 21 July 2025)."},{"key":"4447_CR3","doi-asserted-by":"publisher","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","volume":"2","author":"M Schiffman","year":"2016","unstructured":"Schiffman M, Doorbar J, Wentzensen N, De Sanjos\u00e9 S, Fakhry C, Monk BJ, et al. Carcinogenic HPV infection. Nat Rev Dis Primers. 2016;2:16086. https:\/\/doi.org\/10.1038\/nrdp.2016.86.","journal-title":"Nat Rev Dis Primers"},{"key":"4447_CR4","unstructured":"Bruni L, Albero G, Serrano B, Mena M, Collado J, G\u00f3mez D, et al. Human papillomavirus and related diseases in Spain. ICO\/IARC information Centre on HPV and Cancer; (2023)."},{"key":"4447_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2506765","author":"AR Kreimer","year":"2025","unstructured":"Kreimer AR, Porras C, Liu D, Hildesheim A, Carvajal LJ, Ocampo R, et al. Noninferiority of one HPV vaccine dose to two doses. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2506765.","journal-title":"N Engl J Med"},{"issue":"12","key":"4447_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121413","volume":"9","author":"S Kamolratanakul","year":"2021","unstructured":"Kamolratanakul S, Pitisuttithum P. Human papillomavirus vaccine efficacy and effectiveness against cancer. Vaccines. 2021;9(12):1413. https:\/\/doi.org\/10.3390\/vaccines9121413.","journal-title":"Vaccines"},{"key":"4447_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070135","author":"KS Kechagias","year":"2022","unstructured":"Kechagias KS, Kalliala I, Bowden SJ, Athanasiou A, Paraskevaidi M, Paraskevaidis E, et al. The role of HPV vaccination on HPV infection and recurrence after local surgical treatment: systematic review and meta-analysis. BMJ. 2022. https:\/\/doi.org\/10.1136\/bmj-2022-070135.","journal-title":"BMJ"},{"issue":"2","key":"4447_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ijgo.16120","volume":"169","author":"N Bizzarri","year":"2025","unstructured":"Bizzarri N, Kyrgiou M, De Vincenzo R, Zapardiel I, Razumova Z, Taumberger N, et al. Prophylactic HPV vaccination in HPV-related gynaecologic cancers: ESGO prevention committee opinion. Int J Gynecol Obstet. 2025;169(2):597\u2013604. https:\/\/doi.org\/10.1002\/ijgo.16120.","journal-title":"Int J Gynecol Obstet"},{"issue":"7","key":"4447_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2018.10400","volume":"320","author":"J Melnikow","year":"2018","unstructured":"Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for cervical cancer with high-risk HPV testing. JAMA. 2018;320(7):687\u2013705. https:\/\/doi.org\/10.1001\/jama.2018.10400.","journal-title":"JAMA"},{"key":"4447_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008587.pub2","author":"G Koliopoulos","year":"2017","unstructured":"Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017. https:\/\/doi.org\/10.1002\/14651858.CD008587.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"4447_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12061508","volume":"12","author":"A Macios","year":"2022","unstructured":"Macios A, Nowakowski A. False negative results in cervical cancer screening\u2014risks, reasons and implications for public health. Diagnostics. 2022;12(6):1508. https:\/\/doi.org\/10.3390\/diagnostics12061508.","journal-title":"Diagnostics"},{"issue":"10316","key":"4447_CR12","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","volume":"398","author":"M Falcaro","year":"2021","unstructured":"Falcaro M, Casta\u00f1on A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. Effects of the national HPV vaccination programme in England on cervical cancer and CIN3 incidence. Lancet. 2021;398(10316):2084\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(21)02178-4.","journal-title":"Lancet"},{"issue":"14","key":"4447_CR13","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","volume":"383","author":"J Lei","year":"2020","unstructured":"Lei J, Ploner A, Elfstr\u00f6m KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1917338.","journal-title":"N Engl J Med"},{"key":"4447_CR14","unstructured":"Ministerio de Sanidad. Actualizaci\u00f3n de las recomendaciones de vacunaci\u00f3n frente a VPH. Comisi\u00f3n de Salud P\u00fablica; 2024. Available at: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/comoTrabajamos\/docs\/VPH_recomendaciones_vacunacion_estrategia1dosis.pdf (Accessed 18 Aug 2025)."},{"key":"4447_CR15","unstructured":"Ministerio de Sanidad. Documento de consenso para el programa poblacional de cribado de c\u00e1ncer de c\u00e9rvix. 2024. Available at: https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/cribado\/cribadoCancer\/cancerCervix\/docs\/requisitosRecomendaciones_CribadoCervix.pdf (Accessed 25 Sep 2025)."},{"key":"4447_CR16","unstructured":"Spanish Society of Medical Oncology (2024) Cancer figures in Spain 2023. https:\/\/seom.org\/images\/publicaciones\/informes-seom-de-evaluacion-de-farmacos\/LAS_CIFRAS_2024.pdf. (Accessed 13 Oct 2025)."},{"key":"4447_CR17","unstructured":"IARC Global Cancer Observatory. Available at: https:\/\/gco.iarc.fr\/en (Accessed 13 Oct 2025)."},{"key":"4447_CR18","unstructured":"Centers for Disease Control and Prevention. HPV vaccination recommendations. Available at: https:\/\/www.cdc.gov\/vaccines\/vpd\/hpv\/hcp\/recommendations.html (Accessed 18 Aug 2025)."},{"key":"4447_CR19","unstructured":"Australian Government Department of Health. Human papillomavirus immunisation service. Available at: https:\/\/www.health.gov.au\/topics\/immunisation\/vaccines\/human-papillomavirus-hpv-immunisation-service (Accessed 18 Aug 2025)."},{"key":"4447_CR20","unstructured":"Instituto Nacional de Estad\u00edstica. Available at: https:\/\/www.ine.es (Accessed 18 Aug 2025)."},{"key":"4447_CR21","unstructured":"American College of Obstetricians and Gynecologists. Updated cervical cancer screening guidelines. Available at: https:\/\/www.acog.org\/ (Accessed 27 Sep 2025)."},{"key":"4447_CR22","unstructured":"Australian Government. National cervical screening program. Available at: https:\/\/www.health.gov.au\/our-work\/national-cervical-screening-program\/about-the-national-cervical-screening-program (Accessed 27 Sep 2025)."},{"issue":"8","key":"4447_CR23","doi-asserted-by":"publisher","first-page":"e1115","DOI":"10.1016\/S2214-109X(22)00055-1","volume":"10","author":"L Bruni","year":"2022","unstructured":"Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage in 202 countries and territories. Lancet Glob Health. 2022;10(8):e1115\u201327. https:\/\/doi.org\/10.1016\/S2214-109X(22)00055-1.","journal-title":"Lancet Glob Health"},{"issue":"6","key":"4447_CR24","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/ijc.30922","volume":"141","author":"MT Faber","year":"2017","unstructured":"Faber MT, Sand FL, Albieri V, Norrild B, Kjaer SK, Verdoodt F. Prevalence and type distribution of human papillomavirus in vulvar carcinoma and intraepithelial neoplasia. Int J Cancer. 2017;141(6):1161\u20139. https:\/\/doi.org\/10.1002\/ijc.30922.","journal-title":"Int J Cancer"},{"issue":"12","key":"4447_CR25","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1111\/1471-0528.17467","volume":"131","author":"J Huang","year":"2024","unstructured":"Huang J, Chan SC, Pang WS, Mak FY, Fung YC, Lok V, et al. Incidence, risk factors and trends in vaginal cancer: a global population-based study. BJOG. 2024;131(12):1660\u201372. https:\/\/doi.org\/10.1111\/1471-0528.17467.","journal-title":"BJOG"},{"key":"4447_CR26","unstructured":"Cancer Research UK. Penile cancer: risks and causes. Available at: https:\/\/www.cancerresearchuk.org\/about-cancer\/penile-cancer\/risks-causes (Accessed 23 Oct 2025)."},{"issue":"1","key":"4447_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13027-024-00568-1","volume":"19","author":"F Ebrahimi","year":"2024","unstructured":"Ebrahimi F, Rasizadeh R, Jafari S, Baghi HB. Prevalence of HPV in anal cancer: the role of infection and inflammation. Infect Agent Cancer. 2024;19(1):63. https:\/\/doi.org\/10.1186\/s13027-024-00568-1.","journal-title":"Infect Agent Cancer"},{"issue":"2","key":"4447_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/v15020451","volume":"15","author":"SK Katirachi","year":"2023","unstructured":"Katirachi SK, Gr\u00f8nlund MP, Jakobsen KK, Gr\u00f8nh\u00f8j C, Von Buchwald C. The prevalence of HPV in oral cavity squamous cell carcinoma. Viruses. 2023;15(2):451. https:\/\/doi.org\/10.3390\/v15020451.","journal-title":"Viruses"},{"issue":"5","key":"4447_CR29","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41571-022-00617-7","volume":"19","author":"M Lechner","year":"2022","unstructured":"Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer. Nat Rev Clin Oncol. 2022;19(5):306\u201327. https:\/\/doi.org\/10.1038\/s41571-022-00617-7.","journal-title":"Nat Rev Clin Oncol"},{"key":"4447_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.107057","volume":"159","author":"BY Zhao","year":"2024","unstructured":"Zhao BY, Hirayama S, Goss D, Zhao Y, Faden DL. HPV-associated nasopharyngeal carcinoma: a systematic review and meta-analysis. Oral Oncol. 2024;159:107057. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.107057.","journal-title":"Oral Oncol"},{"issue":"1","key":"4447_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/01945998211036486","volume":"166","author":"EJ Patel","year":"2022","unstructured":"Patel EJ, Oliver JR, Jacobson AS, Li Z, Hu KS, Tam M, et al. Human papillomavirus in hypopharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2022;166(1):109\u201317. https:\/\/doi.org\/10.1177\/01945998211036486.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"4447_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/infdis\/jis698","volume":"207","author":"X Li","year":"2013","unstructured":"Li X, Gao L, Li H, Gao J, Yang Y, Zhou F, et al. HPV infection and laryngeal cancer risk: systematic review and meta-analysis. J Infect Dis. 2013;207(3):479\u201388. https:\/\/doi.org\/10.1093\/infdis\/jis698.","journal-title":"J Infect Dis"},{"issue":"4","key":"4447_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/0009922816660541","volume":"56","author":"EY Petrosky","year":"2017","unstructured":"Petrosky EY, Liu G, Hariri S, Markowitz LE. Human papillomavirus vaccination and age at first sexual activity. Clin Pediatr (Phila). 2017;56(4):363\u201370. https:\/\/doi.org\/10.1177\/0009922816660541.","journal-title":"Clin Pediatr (Phila)"},{"issue":"7","key":"4447_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab111","volume":"8","author":"VS Prabhu","year":"2021","unstructured":"Prabhu VS, Roberts CS, Kothari S, Niccolai L. Median age at HPV infection among women in the United States: a model-based analysis informed by real-world data. Open Forum Infect Dis. 2021;8(7):ofab111. https:\/\/doi.org\/10.1093\/ofid\/ofab111.","journal-title":"Open Forum Infect Dis"},{"issue":"38","key":"4447_CR35","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.1016\/j.vaccine.2020.04.021","volume":"38","author":"A Phillips","year":"2020","unstructured":"Phillips A, Hickie M, Totterdell J, Brotherton J, Dey A, Hill R, et al. Adverse events following HPV vaccination: 11 years of surveillance in Australia. Vaccine. 2020;38(38):6038\u201346. https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.021.","journal-title":"Vaccine"},{"issue":"1","key":"4447_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.21873\/cdp.10283","volume":"4","author":"T Pisani","year":"2024","unstructured":"Pisani T, Cenci M. Prevalence of multiple high-risk human papillomavirus infections in cervical cancer screening in Lazio region, Italy. Cancer Diagn Progn. 2024;4(1):42\u20135. https:\/\/doi.org\/10.21873\/cdp.10283.","journal-title":"Cancer Diagn Progn"},{"issue":"13","key":"4447_CR37","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1056\/NEJMoa1608566","volume":"376","author":"NM Scheller","year":"2017","unstructured":"Scheller NM, Pasternak B, M\u00f8lgaard-Nielsen D, Svanstr\u00f6m H, Hviid A. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes. N Engl J Med. 2017;376(13):1223\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1608566.","journal-title":"N Engl J Med"},{"issue":"8","key":"4447_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161403","volume":"11","author":"M Castillo","year":"2016","unstructured":"Castillo M, Astudillo A, Clavero O, Velasco J, Ib\u00e1\u00f1ez R, De Sanjos\u00e9 S. Poor cervical cancer screening attendance and false negatives: A call for organized screening. PLoS ONE. 2016;11(8):e0161403. https:\/\/doi.org\/10.1371\/journal.pone.0161403.","journal-title":"PLoS ONE"},{"key":"4447_CR39","unstructured":"UK Health Security Agency. Spotlight on sexually transmitted infections in the South West, 2022 data. Available at: https:\/\/www.gov.uk\/government\/publications\/sexually-transmitted-infections-south-west-data\/spotlight-on-sexually-transmitted-infections-in-the-south-west-2022-data (Accessed 12 Aug 2025)."},{"issue":"5","key":"4447_CR40","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.gaceta.2017.11.010","volume":"32","author":"P Navarro-Illana","year":"2018","unstructured":"Navarro-Illana P, Navarro-Illana E, Vila-Candel R, D\u00edez-Domingo J. Drivers for HPV vaccination in Valencia, Spain. Gac Sanit. 2018;32(5):454\u20138. https:\/\/doi.org\/10.1016\/j.gaceta.2017.11.010.","journal-title":"Gac Sanit"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04447-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04447-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04447-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:02:20Z","timestamp":1792803740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04447-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["4447"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04447-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Alejandro Gallego Martinez and Antonio Gonzalez-Martin declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Dr. Luis Chiva de Agustin has received honoraria for lectures from the following companies: Medtronic, GSK, and AstraZeneca.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is based exclusively on previously published data.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}